SCHEMBL6784075

SCHEMBL6784075

COC(=O)c1ccc(Cl)cc1NC(=O)/C=C(/C)c1ccc(Cl)c(Cl)c1

nearest known ligand 0.52

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.51
MEN1 O00255 5/20 0.51
KMT2A Q03164 5/20 0.51
HPGD P15428 4/20 0.51
HTT P42858 1/20 0.50
KDM4E B2RXH2 4/20 0.47
ATM Q13315 1/20 0.47
LMNA P02545 2/20 0.45
GLA P06280 1/20 0.44
ABL1 P00519 1/20 0.43
PKM P14618 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43
TERT O14746 3/20 0.43
MAPT P10636 1/20 0.43
S1PR1 P21453 1/20 0.41
S1PR3 Q99500 1/20 0.41
NPC1 O15118 1/20 0.40
RAB9A P51151 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6785976 0.91 TERT (0.44) ALDH1A1MEN1KMT2AHPGDHTT
SCHEMBL6786826 0.88 TERT (0.55) ALDH1A1MEN1KMT2AHPGDKDM4E
SCHEMBL6784249 0.87 TERT (0.56) ALDH1A1MEN1KMT2AHPGDHTT
SCHEMBL6787843 0.85 TERT (0.61) ALDH1A1MEN1KMT2AHPGDHTT
SCHEMBL6787614 0.85 KDM4E (0.53) ALDH1A1MEN1KMT2AHPGDHTT
SCHEMBL6782114 0.85 SMN1; SMN2 (0.50) ALDH1A1MEN1KMT2AHPGDHTT
SCHEMBL6786604 0.84 TERT (0.53) ALDH1A1MEN1KMT2AHPGDKDM4E
SCHEMBL6791903 0.83 TERT (0.43) ALDH1A1MEN1KMT2AHPGDHTT
SCHEMBL6785982 0.82 ALDH1A1 (0.46) ALDH1A1MEN1KMT2AHPGDHTT
SCHEMBL6787326 0.82 TERT (0.42) ALDH1A1MEN1KMT2AHPGDKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6727250-B2 ADMINISTERING COMPOUNDS SUCH AS TRANS-3-(NAPHTH-2-YL)-BUT-2-ENOIC ACID-N-(2-CARBOXY-PHENYL)-AMIDE OR LIKE FOR THERAPY OF CONDITIONS ASSOCIATED WITH INCREASED TELOMERASE ACTIVITY, E.G. TUMOUR DISEASES BOEHRINGER INGELHEIM PHARMA KG (DE) 2004-04-27 US disclosed
US-20020099089-A1 Carboxylic acid amides, pharmaceutical compositions containing these compounds, their use and preparation BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2002-07-25 US disclosed
US-6362210-B1 ANTITUMOR, ANTICANCER AGENT BOEHRINGER INGELHEIM PHARMA KG (DE) 2002-03-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020099089-A1 Carboxylic acid amides, pharmaceutical compositions containing these compounds, their use and preparation TERT, NAT1, POT1 ALDH1A1 102/4885MEN1 896/4885KMT2A 490/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.